History of Hemophilia
Although modern replacement therapies emerged only in recent decades, hemophilia has been recognized since antiquity. Early historical records document human understanding of this genetic bleeding condition evolving over two millennia.
Ancient Records & Early Descriptions
The earliest documented references to inherited bleeding tendencies appear in Jewish Talmudic texts from the second century AD, where male infants were exempted from circumcision if elder brothers had suffered fatal hemorrhage. In the twelfth century, the physician Moses Maimonides recognized the maternal inheritance pattern, applying exemptions to sons of the same mother by different fathers.
In 1803, Philadelphia physician Dr. John Conrad Otto published the first modern clinical account describing an inherited bleeding predisposition that affected exclusively males while being transmitted through healthy females.
Etymology & The Distinction of Types
The termhaemorrhaphilia(later shortened to hemophilia) was first introduced in 1828 by Hopff at the University of Zurich. In 1952, researchers distinguished Hemophilia B (Factor IX deficiency) from Hemophilia A (Factor VIII deficiency), naming itChristmas Diseaseafter the first identified patient.
The "Royal Disease"
Hemophilia gained historic prominence as The Royal Disease due to its spread through European monarchies via Queen Victoria of the United Kingdom (1819–1901), who was an obligate carrier through a spontaneous de novo mutation. Through the marriages of her daughters Alice and Beatrice, hemophilia was introduced into the royal households of Russia, Spain, and Germany. The most notable affected royal was Tsarevich Alexei of Russia, son of Tsar Nicholas II.
Evolution of Treatment & Modern Research
Treatment progressed dramatically from whole blood transfusions in the early 20th century to cryoprecipitate in the 1960s, lyophilized plasma-derived concentrates in the 1970s, and recombinant (bioengineered) clotting factors with viral inactivation in the 1990s. Today, gene therapy and non-factor replacement therapies represent the forefront of scientific research aimed at achieving a long-term functional cure.